<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520688</url>
  </required_header>
  <id_info>
    <org_study_id>RC#5255</org_study_id>
    <nct_id>NCT01520688</nct_id>
  </id_info>
  <brief_title>Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth</brief_title>
  <official_title>A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Penn Allegheny Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Penn Allegheny Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children with mild persistent asthma that have asthma symptoms once or twice a week and use a&#xD;
      daily controller, while children with mild intermittent asthma rarely have asthma symptoms&#xD;
      and do not use a daily controller. Inhaled corticosteroids are the standard treatment for&#xD;
      mild peristent asthma. The purpose of this study is to measure children rate of growth while&#xD;
      on different inhaled corticosteroids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, cross over study evaluating the effect of Flovent Discus 100 mcg BID vs QVAR 80&#xD;
      mcg BID vs Pulmicort Flexhaler 180 mcg BID on short term growth in pediatric subjects with&#xD;
      asthma.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. The primary objective of this study is to compare the effect of Flovent Diskus 100 mcg&#xD;
           BID versus Pulmicort Flexhaler 180 mcg BID on short-term lower leg growth velocity as&#xD;
           measured by knemometry in pediatric subjects with mild asthma.&#xD;
&#xD;
        2. The secondary objective of this study is to compare the effect of Flovent Diskus 100 mcg&#xD;
           BID versus QVAR 80 mcg BID on short-term lower leg growth velocity as measured by&#xD;
           knemometry in pediatric subjects with mild asthma.&#xD;
&#xD;
      Aims:&#xD;
&#xD;
        1. The primary aim is to show that there is a growth suppressive effect of Pulmicort&#xD;
           Flexhaler 180 mcg BID versus Flovent Diskus 100 mcg BID in children with mild asthma.&#xD;
&#xD;
        2. The secondary aim to show that there is a growth suppressive effect of QVAR 80 mcg BID&#xD;
           versus Flovent Diskus 100 mcg BID in children with mild asthma.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. The primary hypothesis is that treatment with Pulmicort Flexhaler 180mcg BID as compared&#xD;
           to Flovent Diskus 100 mcg BID has a growth suppressive effect on lower leg length as&#xD;
           assessed by knemometry in pediatric subjects with mild asthma.&#xD;
&#xD;
        2. The secondary hypothesis is that treatment with QVAR 80 mcg BID as compared to Flovent&#xD;
           Diskus 100 mcg BID has a growth suppressive effect on lower leg length as assessed by&#xD;
           knemometry in pediatric subjects with mild asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID.</measure>
    <time_frame>1 yr</time_frame>
    <description>Short-term lower leg growth as assessed by knemometry in pediatric subjects with mild asthma treated with Flovent Discus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-term Lower Leg Growth During Treatment With Flovent Discus 100 mcg BID or QVAR 80 mcg BID.</measure>
    <time_frame>1 yr</time_frame>
    <description>Short-term lower leg growth as assessed by knemometry in pediatric subjects with mild asthma during treatment with Flovent Discus 100 mcg BID or QVAR 80 mcg BID.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1 Treatment Sequence, FPQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Treatment Sequence, FQP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Treatment Sequence, PFQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2 Pulmicort Period 4 Flovent Period 6 QVAR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4-Treatment Sequence, PQF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2 Pulmicort Period 4 QVAR Period 6 Flovent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Treatment Sequence, QFP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2 QVAR Period 4 Flovent Period 6 Pulmicort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 Treatment Sequence, QPF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2 QVAR Period 4 Pulmicort Period 6 Flovent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone, Budesonide, Beclomethasone</intervention_name>
    <description>Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid</description>
    <arm_group_label>1 Treatment Sequence, FPQ</arm_group_label>
    <other_name>Flovent Diskus</other_name>
    <other_name>Pulmicort Flexhaler</other_name>
    <other_name>QVAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone, Beclomethasone, Budesonide</intervention_name>
    <description>Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID</description>
    <arm_group_label>2 Treatment Sequence, FQP</arm_group_label>
    <other_name>Flovent Diskus</other_name>
    <other_name>Pulmicort Flexhaler</other_name>
    <other_name>QVAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide, Fluticasone, Beclomethasone</intervention_name>
    <description>Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID</description>
    <arm_group_label>3 Treatment Sequence, PFQ</arm_group_label>
    <other_name>Pulmicort Flexhaler</other_name>
    <other_name>Flovent Diskus</other_name>
    <other_name>QVAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide, Beclomethasone, Fluticasone</intervention_name>
    <description>Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID</description>
    <arm_group_label>4-Treatment Sequence, PQF</arm_group_label>
    <other_name>Pulmicort Flexhaler</other_name>
    <other_name>QVAR</other_name>
    <other_name>Flovent Diskus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone, Fluticasone, Budesonide</intervention_name>
    <description>Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID</description>
    <arm_group_label>5 Treatment Sequence, QFP</arm_group_label>
    <other_name>QVAR</other_name>
    <other_name>Flovent Diskus</other_name>
    <other_name>Pulmicort Flexhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone, Budesonide, Fluticasone</intervention_name>
    <description>Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID</description>
    <arm_group_label>6 Treatment Sequence, QPF</arm_group_label>
    <other_name>QVAR</other_name>
    <other_name>Pulmicort Flexhaler</other_name>
    <other_name>flovent Diskus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects will include females (6 to 9 years of age) and males (6 to 11 years of age).&#xD;
&#xD;
          2. All subjects must have a history of physician diagnosed mild intermittent or mild&#xD;
             persistent asthma as documented by PCP medical record or detailed history by study&#xD;
             investigator.&#xD;
&#xD;
          3. All subjects must have a height within normal limits (5th to 95th percentile) and no&#xD;
             history of abnormal growth as assessed by medical history.&#xD;
&#xD;
          4. All subjects must be pre-pubertal (Tanner Stage 1 Sexual Maturity) as assessed by&#xD;
             physical examination.&#xD;
&#xD;
          5. Subjects may be on current treatment with montelukast as this drug does not affect&#xD;
             growth. If a subject is on montelukast at screening/baseline, they will remain on a&#xD;
             stable dose throughout the study.&#xD;
&#xD;
          6. Subjects must be willing to comply with study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects will be excluded if they have asthma greater than mild persistent severity as&#xD;
             defined by NHLBI guidelines.&#xD;
&#xD;
          2. Subjects will be excluded if they used any systemic or nasal steroids within the past&#xD;
             60 days.&#xD;
&#xD;
          3. Subjects will be excluded if they had more than one burst of systemic steroids within&#xD;
             the past year.&#xD;
&#xD;
          4. Subjects will be excluded if their baseline FEV1 is &lt; 80% predicted.&#xD;
&#xD;
          5. Subjects will be excluded if they have any other serious systemic disease other than&#xD;
             asthma.&#xD;
&#xD;
          6. Subjects will be excluded if they have taken any medication known to affect growth&#xD;
             i.e. ADHD medications within the past 60 days&#xD;
&#xD;
          7. Subjects will be excluded if they have a history of allergy to any of the study&#xD;
             medications, milk protein or lactose.&#xD;
&#xD;
          8. Subjects will be excluded if they have active chickenpox or measles or recent exposure&#xD;
             to chickenpox or measles.&#xD;
&#xD;
          9. Subjects will be excluded if they have any history of tuberculosis of the respiratory&#xD;
             tract.&#xD;
&#xD;
         10. Subjects will be excluded if they have any active fungal, bacterial, viral or&#xD;
             parasitic infections.&#xD;
&#xD;
         11. Subjects will be excluded if they have any history of herpes simplex infection of the&#xD;
             eye.&#xD;
&#xD;
         12. Subjects will be excluded if they have taken any immunosuppressive drugs within the&#xD;
             past 2 months.&#xD;
&#xD;
         13. Subjects will be excluded if they have any history of Churg-Strauss syndrome or other&#xD;
             eosinophilic disorders.&#xD;
&#xD;
         14. Subjects will be excluded if an investigator deems they have any mental or development&#xD;
             health issues, such as autism, moderate to severe mental retardation or severe&#xD;
             ADHD,that interferes with their ability to complete the knemometry measurements.&#xD;
&#xD;
         15. Subjects will be excluded if an investigator deems they have any physical issues, such&#xD;
             as inability to sit independently or amputation of lower leg, that interferes with&#xD;
             their ability to complete the knemometry measurements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah A Gentile, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allegheny Singer Research Institute/Allegheny General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Alliance-Greentree Division</name>
      <address>
        <city>Green Tree</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <results_first_submitted>November 17, 2016</results_first_submitted>
  <results_first_submitted_qc>September 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2020</results_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West Penn Allegheny Health System</investigator_affiliation>
    <investigator_full_name>Deborah Gentile</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Mild persistent or mild intermittent asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 Treatment Sequence, FPQ</title>
          <description>Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR&#xD;
Fluticasone, Budesonide, Beclomethasone: Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid</description>
        </group>
        <group group_id="P2">
          <title>2 Treatment Sequence, FQP</title>
          <description>Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort&#xD;
Fluticasone, Beclomethasone, Budesonide: Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID</description>
        </group>
        <group group_id="P3">
          <title>3 Treatment Sequence, PFQ</title>
          <description>Period 2 Pulmicort Period 4 Flovent Period 6 QVAR&#xD;
Budesonide, Fluticasone, Beclomethasone: Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID</description>
        </group>
        <group group_id="P4">
          <title>4-Treatment Sequence, PQF</title>
          <description>Period 2 Pulmicort Period 4 QVAR Period 6 Flovent&#xD;
Budesonide, Beclomethasone, Fluticasone: Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID</description>
        </group>
        <group group_id="P5">
          <title>5 Treatment Sequence, QFP</title>
          <description>Period 2 QVAR Period 4 Flovent Period 6 Pulmicort&#xD;
Beclomethasone, Fluticasone, Budesonide: Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID</description>
        </group>
        <group group_id="P6">
          <title>6 Treatment Sequence, QPF</title>
          <description>Period 2 QVAR Period 4 Pulmicort Period 6 Flovent&#xD;
Beclomethasone, Budesonide, Fluticasone: Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID</description>
        </group>
        <group group_id="P7">
          <title>Enrolled But Not Randomized.</title>
          <description>These subjects were consented but not randomized.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID.</title>
        <description>Short-term lower leg growth as assessed by knemometry in pediatric subjects with mild asthma treated with Flovent Discus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID.</description>
        <time_frame>1 yr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flovent Discus 100 mcg BID</title>
          </group>
          <group group_id="O2">
            <title>Pulmicort Flexhaler 180 mcg BID</title>
          </group>
        </group_list>
        <measure>
          <title>Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID.</title>
          <description>Short-term lower leg growth as assessed by knemometry in pediatric subjects with mild asthma treated with Flovent Discus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID.</description>
          <units>mm/wk</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0.21" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.05" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Lower Leg Growth During Treatment With Flovent Discus 100 mcg BID or QVAR 80 mcg BID.</title>
        <description>Short-term lower leg growth as assessed by knemometry in pediatric subjects with mild asthma during treatment with Flovent Discus 100 mcg BID or QVAR 80 mcg BID.</description>
        <time_frame>1 yr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flovent Discus 100 mcg BID</title>
          </group>
          <group group_id="O2">
            <title>QVAR 80 mcg BID</title>
          </group>
        </group_list>
        <measure>
          <title>Short-term Lower Leg Growth During Treatment With Flovent Discus 100 mcg BID or QVAR 80 mcg BID.</title>
          <description>Short-term lower leg growth as assessed by knemometry in pediatric subjects with mild asthma during treatment with Flovent Discus 100 mcg BID or QVAR 80 mcg BID.</description>
          <units>mm/wk</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0.21" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.38" lower_limit="0.22" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Flovent Discus 100 mcg BID</title>
        </group>
        <group group_id="E2">
          <title>Pulmicort Flexhaler 180 mcg BID</title>
        </group>
        <group group_id="E3">
          <title>QVAR 80 mcg BID</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Colds/viral illnesses</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bodily injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening allergies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory infections</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deborah Gentile, MD</name_or_title>
      <organization>Allegheny Health Network</organization>
      <phone>412-359-4099</phone>
      <email>dgentile@ahn.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

